Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Anthrax Indication Strategy Report 2026: Anthrax protective antigen, Trials and Deals
23 July 2026
2026 Anthrax strategy: epidemiology, Anthrax protective antigen biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Tetanus Indication Strategy Report 2026: Tetanospasmin, Trials and Deals
23 July 2026
2026 Tetanus strategy: epidemiology, Tetanospasmin biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Diphtheria Indication Strategy Report 2026: Diphtheria toxin, Trials and Deals
23 July 2026
2026 Diphtheria strategy: epidemiology, Diphtheria toxin biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Botulism Indication Strategy Report 2026: Botulinum toxin, Trials and Deals
23 July 2026
2026 Botulism strategy: epidemiology, Botulinum toxin biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Leptospirosis Indication Strategy Report 2026: Leptospira LigA, Trials and Deals
23 July 2026
2026 Leptospirosis strategy: epidemiology, Leptospira LigA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Scrub typhus Indication Strategy Report 2026: Orientia DNA gyrase, Trials and Deals
23 July 2026
2026 Scrub typhus strategy: epidemiology, Orientia DNA gyrase biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Rickettsiosis Indication Strategy Report 2026: Rickettsia DNA gyrase, Trials and Deals
23 July 2026
2026 Rickettsiosis strategy: epidemiology, Rickettsia DNA gyrase biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Tularemia Indication Strategy Report 2026: Francisella LpxC, Trials and Deals
23 July 2026
2026 Tularemia strategy: epidemiology, Francisella LpxC biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Legionnaires disease Indication Strategy Report 2026: Legionella LpxC, Trials and Deals
23 July 2026
2026 Legionnaires disease strategy: epidemiology, Legionella LpxC biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Q fever Indication Strategy Report 2026: Coxiella DNA gyrase, Trials and Deals
23 July 2026
2026 Q fever strategy: epidemiology, Coxiella DNA gyrase biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Brucellosis Indication Strategy Report 2026: Brucella DNA gyrase, Trials and Deals
23 July 2026
2026 Brucellosis strategy: epidemiology, Brucella DNA gyrase biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Melioidosis Indication Strategy Report 2026: Burkholderia LpxC, Trials and Deals
23 July 2026
2026 Melioidosis strategy: epidemiology, Burkholderia LpxC biology, clinical competition, recent deals, unmet need and market attractiveness.